Bacteriophage therapy - Lysigen
Alternative Names: BACTELIDE; PL-03-BM; Topical bacteriophage therapy-LysigenLatest Information Update: 01 Feb 2024
At a glance
- Originator Phagelux
- Developer Lysigen
- Class Antibacterials; Bacteriophages
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pressure ulcer
Most Recent Events
- 25 Mar 2021 Preclinical trials in Pressure ulcer (Adjunctive treatment) in China (Topical)
- 25 Mar 2021 Phagelux plans a phase I/II trial for Pressure ulcer (Adjunctive treatment) in the US (NCT04815798)